Researchers from the University of Oxford have recently reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG – with promising results identified.

The RAB001 trial was conducted at the University and is the first time the novel rabies vaccine has been used in human volunteers. The aim of the study was to look at safety and measure immune responses from the vaccine by analysing levels of rabies neutralising antibodies – a powerful marker of successful rabies vaccination.